Clinuvel Pharmaceuticals Ltd (CUVL) — research page

US · us-cm-kg/NASDAQ/CUVL · as of 2026-11-08

Identity and listing

The issuer is Clinuvel Pharmaceuticals Ltd, listed on NASDAQ under ticker CUVL, with ISIN US1887691038 and LEI 5299004VJH3VCYLK6519. Its security type is non-operating entity type (other), its segment is not on the record, its sector is 8880 American Depositary Receipts, and its jurisdiction is Australia. Its listing status is listed, not halted.

The disclosure read

The record holds 35 filings across 28 filing days in the window 2025-11-08 to 2026-11-08, comprising 1 prospectus, 18 regulatory filings and 16 results. The median gap between filing days is 8 days, and the median latency from the latest filing to the record date is 9 days. The NASDAQ median cadence gap is 6.0 days across 4359 issuers, with a median of 52 filings and a median latency of 5.0 days. The sector node 8880 American Depositary Receipts has one issuer, so no median is stated. The latest filing is dated 2026-10-30 and is of type results.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor of record is not on the record, because the latest annual report cover carries no dei:AuditorName tag. Its location is not on the record. The record holds no auditor changes.

Events and halts

The record holds one listing dated 2026-07-17. It holds no delisting, no name change, and no dated domicile change, and the segment move is not on the record. The issuer is listed, not halted.

Orderability

The orderability outcome is not determinable, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

The issuer's investor-relations page names 8 research houses: Bioshares, MA Moelis Australia, Jefferies Australia, Morningstar, Wilsons Advisory, Bell Potter Securities, Morgans Financial and Barrenjoey.

Open research

No openly published research notes were found on the record.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The sealed years that hold the issuer are 2021, 2025 and 2026. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.

Sources

9 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001290877.json (identity.jurisdiction)

10.4

https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)

10.5

https://mcp.us-cm-kg.ai/events/NASDAQ/CUVL (the disclosure lines)

10.6

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.7

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.8

https://www.clinuvel.com/investor/analyst-coverage/ (coverage)

10.9

https://mcp.us-cm-kg.ai/record/NASDAQ/CUVL (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"US1887691038"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:f2b0227c4726f0e3.